Healthcare Digital June 2021 | Page 124

A brief history of Takeda
SUPPLY CHAIN

“ Ultimately , what you ' re trying to do is get a faster , more accurate diagnosis , leading to a specific therapy ”

CHRIS EASTON GLOBAL COMMERCIAL LEAD , TAKEDA

A brief history of Takeda

1781 : 32-year-old Chobei Takeda starts a business in Osaka , Japan , selling traditional medicine to local medicine merchants and doctors . 1871 : Chobei Takeda IV begins purchasing Western medicines such as quinine , an antimalaria drug . 1895 : Takeda buys Uchibayashi Drug Works to establish its own factory in Osaka , becoming a pharmaceutical manufacturer . 1925 : Chobei Takeda & Co ., Ltd . becomes an incorporated company , with a capital of 5.3 million yen and Chobei Takeda V as president . In 1943 it changed its name to Takeda Pharmaceutical Industries . 1949 : Takeda becomes a publiclytraded company . 1978 : The company establishes bases in Germany , France and Italy to expand sales to Europe . 1991 : Anti-peptic ulcer medicine Lansoprazole launches in Europe , now sold in over 90 countries . 2018 - 2019 : Takeda opens global headquarters in Tokyo and is listed on the New York Stock Exchange . In 2019 it acquired Shire , a UK-founded biopharmaceutical company . normalised , and menstrual flow goes down to normal levels . That ' s actually a massive outcome for someone who has been living with two-week-long periods that bleed through clothing every month . Suddenly for just four or five days , they can use regular tampons and pads . That ' s a huge improvement to life ."
The field of rare blood disorders typically hasn ' t seen the same amount of attention focused on it - at least in terms of tech innovation - as other chronic illnesses like diabetes . " Rare blood disorders are difficult to show returns on because you ' ve got small patient numbers and often high costs . But if we think about the total patient journey , we could use technology to triage vast numbers of patients and data into more specific diagnosis boxes , so that what is then presented to physicians are smaller groups , of the more likely issues ."
124 June 2021